Clinical trial
A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Tolerability of Two Titration Schedules for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults With an Inadequate Response to Antidepressant Therapy (the FORWARD-1 Study)
NCT02085135 is registered in ClinicalTrials.gov with Alkermes, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Tolerability of Two Titration Schedules for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults With an Inadequate Response to Antidepressant Therapy (the FORWARD-1 Study)
- Lead sponsor
- Alkermes, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- February 28, 2014
- Completion date
- September 30, 2014
- Enrollment
- 66 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.